P=N/A, N=60, Completed, Cairo University

Moreover, AMI suppressed the expression of PD-L1 in cells that had been exposed to or had not been exposed to radiation, whereas radiation enhanced its expression. Because AMI exhibited promising anticancer properties including an interesting, previously unknown immunomodulatory effect, it appears that its potential therapeutic should be verified in an in vivo study.

P=N/A, N=8688, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

P=N/A, N=5000, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

P2, N=190, Recruiting, University of Rochester | Not yet recruiting --> Recruiting

P4, N=40, Recruiting, University of California, Irvine | N=100 --> 40 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P3, N=315, Active, not recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Apr 2026

Except for the blank control group, the remaining 48 mice underwent ectopic transplantation of gastric cancer cells into the axilla and were randomly divided into four groups (n=12 per group): the gastric cancer group, the CIPN model group, the modified Danggui buxue decoction group, and Duloxetine group. Conclusion Modified Danggui buxue decoction may ameliorate pathological damage and pain symptoms in the dorsal root ganglia of a mouse model of oxaliplatin-induced peripheral neurotoxicity following gastric cancer chemotherapy. The mechanism is likely associated with the inhibition of the NF-κB signaling pathway in the dorsal root ganglia and the down regulation of ATM, NF-κB, CCL21, TNF-α, IL-1β, and IL-6 expression.

P3, N=274, Recruiting, Institut Cancerologie de l'Ouest | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028

P1, N=0, Withdrawn, Vanderbilt University Medical Center | N=100 --> 0 | Enrolling by invitation --> Withdrawn

P=N/A, N=200, Not yet recruiting, Haydarpasa Numune Training and Research Hospital

Sex is a crucial biological variable in CIPN, influencing drug efficacy through sex-specific neuroimmune mechanisms and hormonal regulation. These findings underscore the necessity of incorporating sex as a key variable in analgesic development and clinical practice to achieve personalized pain management in CIPN patients.